Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Rhea-AI Summary

Purple Biotech (NASDAQ/TASE: PPBT) received a Nasdaq notice on Oct 16, 2025 that its American Depositary Shares closed below the required $1.00 minimum for 30 consecutive trading days. Under Nasdaq Listing Rule 5810(c)(3)(A) the company has a 180‑day cure period until April 14, 2026 to regain compliance by achieving a closing bid ≥ $1.00 for ten consecutive business days. The notice does not affect the current Nasdaq listing or trading of ADSs, nor its Tel Aviv listing. If noncompliant by April 14, 2026, Purple Biotech may be eligible for a second 180‑day period if it meets market‑value and other listing standards, or face delisting and the option to appeal. The company said it will monitor the ADS price and may consider options such as changing the ADS-to-ordinary share ratio to regain compliance.

Positive

• ADS continue trading on Nasdaq during the 180-day cure period
• Initial compliance window of 180 days until April 14, 2026

Negative

• ADS closing bid below $1.00 for 30 consecutive trading days
• Risk of Nasdaq delisting if compliance not regained by April 14, 2026

REHOVOT, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that on October 16, 2025, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company's American Depositary Shares (ADSs) has been below the minimum $1.00 per share requirement under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive trading days.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial period of 180 calendar days from the date of the notification letter from Nasdaq, or until April 14, 2026, to regain compliance with the minimum bid price requirement. If at any time before April 14, 2026 the closing bid price of the Company's ADSs is USD $1.00 or more for a minimum of ten consecutive business days, the Company will be deemed to have regained compliance with the minimum bid price requirement, following which Nasdaq will provide a written confirmation of compliance and the matter will be closed.

The receipt of the Nasdaq letter has no immediate effect on the Company's Nasdaq listing or the trading of its ADSs, and during the cure period, as may be extended, the Company's ADSs will continue to trade on the Nasdaq Capital Market under the symbol “PPBT”. The letter from Nasdaq also has no bearing on the Company’s listing on the Tel Aviv Stock Exchange, where its ordinary shares are traded under the symbol “PPBT”.

In the event that the Company does not regain compliance by April 14, 2026, the Company may then be eligible for an additional 180 days to regain compliance if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement. To be eligible, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency during the second compliance period, or if the Company is otherwise not eligible, Nasdaq will provide written notice that the ADSs are subject to delisting from the Nasdaq Capital Market. In that event, the Company may appeal the determination to a Nasdaq hearings panel.

The Company intends to monitor the closing bid price of its ADS on the Nasdaq and may, if appropriate, consider implementing available options to cure the deficiency and regain compliance with the minimum bid price requirement within the prescribed compliance period, including potentially changing the ratio between its ADSs and ordinary shares. 

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes CAPTN-3, CM24 and NT219. The Company is advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound’s therapeutic activity to the local tumor microenvironment, thereby potentially increasing the anticipated therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets the 5T4 antigen, which is expressed in a variety of solid tumors and is associated with advanced disease, increased invasiveness, and poor clinical outcomes. IM1305 is the second tri-specific antibody from the platform and targets the TROP2 TAA. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophil extracellular traps is a novel target for the treatment of multiple cancer indications. As proof of concept of these novel pathways, the Company completed a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with the anti-PD-1 checkpoint inhibitor nivolumab and chemotherapy, demonstrating clear and consistent improvement across all efficacy endpoints and the identification of two potential serum biomarkers and other potential tissue biomarkers. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded as a monotherapy and in combination with cetuximab, in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). A Phase 2 study in collaboration with the University of Colorado, to treat R/M SCCHN patients with NT219 in combination with cetuximab or pembrolizumab was initiated. The Company’s corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, the Company is using forward-looking statement in this press release when it discusses its ability to regain compliance under the Nasdaq’s Listing Qualification requirements including by potentially changing the ratio between its ADSs and ordinary shares to regain the $1.00 minimum bid compliance. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219, CM24 and IM1240; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2024 and in our other filings with the U.S. Securities and Exchange Commission (“SEC”), including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date on which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, https://www.sec.gov.

CONTACTS:

Company Contact:
IR@purple-biotech.com

FAQ

What did Purple Biotech (PPBT) receive from Nasdaq on October 16, 2025?

Nasdaq notified Purple Biotech that its ADSs have been below the required $1.00 minimum bid price for 30 consecutive trading days.

How long does Purple Biotech (PPBT) have to regain Nasdaq compliance?

The company has an initial 180‑day cure period ending on April 14, 2026 to regain compliance by achieving $1.00+ for ten consecutive business days.

Will Purple Biotech (PPBT) remain listed and tradable while addressing the Nasdaq notice?

Yes. The notice has no immediate effect and the company's ADSs will continue to trade on Nasdaq under the symbol PPBT during the cure period.

What happens if Purple Biotech (PPBT) does not regain compliance by April 14, 2026?

If noncompliant, the company may be eligible for a second 180‑day period if it meets market value and other listing standards, or Nasdaq may move to delist the ADSs with an option to appeal.

What options did Purple Biotech (PPBT) say it may consider to regain compliance?

The company said it will monitor the ADS price and may consider available options, including potentially changing the ADS-to-ordinary share ratio.